Viatris Cash on Hand 2010-2025 | VTRS
Viatris cash on hand from 2010 to 2025. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
- Viatris cash on hand for the quarter ending March 31, 2025 was $755M, a 25.59% decline year-over-year.
- Viatris cash on hand for 2024 was $0.735B, a 25.92% decline from 2023.
- Viatris cash on hand for 2023 was $0.992B, a 21.27% decline from 2022.
- Viatris cash on hand for 2022 was $1.26B, a 79.68% increase from 2021.
| Viatris Annual Cash on Hand (Millions of US $) |
|
|---|---|
| 2024 | $735 |
| 2023 | $992 |
| 2022 | $1,260 |
| 2021 | $701 |
| 2020 | $844 |
| 2019 | $476 |
| 2018 | $388 |
| 2017 | $292 |
| 2016 | $999 |
| 2015 | $1,236 |
| 2014 | $226 |
| 2013 | $291 |
| 2012 | $350 |
| 2011 | $375 |
| 2010 | $715 |
| 2009 | $456 |
| Viatris Quarterly Cash on Hand (Millions of US $) |
|
|---|---|
| 2025-03-31 | $755 |
| 2024-12-31 | $735 |
| 2024-09-30 | $1,879 |
| 2024-06-30 | $917 |
| 2024-03-31 | $1,015 |
| 2023-12-31 | $992 |
| 2023-09-30 | $1,310 |
| 2023-06-30 | $629 |
| 2023-03-31 | $507 |
| 2022-12-31 | $1,260 |
| 2022-09-30 | $647 |
| 2022-06-30 | $665 |
| 2022-03-31 | $752 |
| 2021-12-31 | $701 |
| 2021-09-30 | $757 |
| 2021-06-30 | $674 |
| 2021-03-31 | $807 |
| 2020-12-31 | $844 |
| 2020-09-30 | $665 |
| 2020-06-30 | $324 |
| 2020-03-31 | $572 |
| 2019-12-31 | $476 |
| 2019-09-30 | $359 |
| 2019-06-30 | $212 |
| 2019-03-31 | $230 |
| 2018-12-31 | $388 |
| 2018-09-30 | $449 |
| 2018-06-30 | $330 |
| 2018-03-31 | $367 |
| 2017-12-31 | $292 |
| 2017-09-30 | $615 |
| 2017-06-30 | $613 |
| 2017-03-31 | $724 |
| 2016-12-31 | $999 |
| 2016-09-30 | $1,257 |
| 2016-06-30 | $6,362 |
| 2016-03-31 | $1,199 |
| 2015-12-31 | $1,236 |
| 2015-09-30 | $587 |
| 2015-06-30 | $440 |
| 2015-03-31 | $277 |
| 2014-12-31 | $226 |
| 2014-09-30 | $200 |
| 2014-06-30 | $194 |
| 2014-03-31 | $243 |
| 2013-12-31 | $291 |
| 2013-09-30 | $365 |
| 2013-06-30 | $277 |
| 2013-03-31 | $294 |
| 2012-12-31 | $350 |
| 2012-09-30 | $367 |
| 2012-06-30 | $348 |
| 2012-03-31 | $298 |
| 2011-12-31 | $375 |
| 2011-09-30 | $552 |
| 2011-06-30 | $490 |
| 2011-03-31 | $663 |
| 2010-12-31 | $715 |
| 2010-09-30 | $665 |
| 2010-06-30 | $881 |
| 2010-03-31 | $599 |
| 2009-12-31 | $456 |
| 2009-09-30 | $682 |
| 2009-06-30 | $516 |
| 2009-03-31 | $533 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $10.504B | $14.739B |
| Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $141.323B | 26.51 |
| CVS Health (CVS) | United States | $85.490B | 10.63 |
| Elevance Health (ELV) | United States | $85.046B | 10.97 |
| Cencora (COR) | United States | $57.007B | 19.83 |
| Natera (NTRA) | United States | $23.468B | 0.00 |
| DiDi Global (DIDIY) | China | $23.015B | 24.45 |
| Labcorp Holdings (LH) | United States | $21.974B | 17.82 |
| BioMerieux (BMXMF) | France | $16.861B | 0.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $13.262B | 0.00 |
| Solventum (SOLV) | United States | $12.973B | 13.73 |
| CochLear (CHEOY) | Australia | $12.633B | 0.00 |
| ICON (ICLR) | Ireland | $11.996B | 11.15 |
| Revvity (RVTY) | United States | $11.361B | 19.55 |
| Avantor (AVTR) | United States | $9.172B | 13.33 |
| Medpace Holdings (MEDP) | United States | $9.062B | 24.07 |
| HealthEquity (HQY) | United States | $9.009B | 39.46 |
| Sonic Healthcare (SKHHY) | Australia | $8.263B | 0.00 |
| Charles River Laboratories (CRL) | United States | $7.289B | 14.28 |
| Amplifon S.p.A (AMFPF) | Italy | $5.378B | 29.44 |
| Bausch + Lomb (BLCO) | Canada | $4.259B | 25.08 |
| BrightSpring Health Services (BTSG) | United States | $4.024B | 36.92 |
| Sotera Health (SHC) | United States | $3.191B | 18.13 |
| Alignment Healthcare (ALHC) | United States | $2.786B | 0.00 |
| Concentras Parent (CON) | United States | $2.716B | 15.70 |
| Surgery Partners (SGRY) | United States | $2.705B | 35.18 |
| GeneDx Holdings (WGS) | United States | $2.594B | 99.89 |
| Organon (OGN) | United States | $2.587B | 2.75 |
| PACS (PACS) | United States | $1.928B | 0.00 |
| Ardent Health (ARDT) | United States | $1.887B | 8.04 |
| Progyny (PGNY) | United States | $1.822B | 40.11 |
| GoodRx Holdings (GDRX) | United States | $1.811B | 36.21 |
| Premier (PINC) | United States | $1.791B | 13.59 |
| Teladoc Health (TDOC) | United States | $1.403B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.158B | 8.81 |
| CareDx (CDNA) | United States | $1.051B | 16.42 |
| Establishment Labs Holdings (ESTA) | $1.034B | 0.00 | |
| Ryman Healthcare (RYHTY) | New Zealand | $0.999B | 0.00 |
| Agilon Health (AGL) | United States | $0.915B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.840B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $0.831B | 7.78 |
| Nutex Health (NUTX) | United States | $0.641B | 9.70 |
| LifeMD (LFMD) | United States | $0.639B | 0.00 |
| Embecta (EMBC) | United States | $0.597B | 4.02 |
| InnovAge Holding (INNV) | United States | $0.545B | 0.00 |
| Enhabit (EHAB) | United States | $0.482B | 39.62 |
| Sonida Senior Living (SNDA) | United States | $0.463B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.463B | 10.42 |
| SBC Medicals (SBC) | United States | $0.442B | 0.00 |
| Omada Health (OMDA) | $0.404B | 0.00 | |
| Performant Healthcare (PHLT) | United States | $0.298B | 0.00 |
| Beauty Health (SKIN) | United States | $0.242B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.237B | 0.00 |
| Oncology Institute (TOI) | United States | $0.210B | 0.00 |
| DocGo (DCGO) | United States | $0.176B | 28.83 |
| So-Young (SY) | China | $0.174B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.123B | 0.00 |
| OncoCyte (IMDX) | United States | $0.099B | 0.00 |
| KindlyMD (NAKA) | United States | $0.092B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.076B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.061B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.055B | 0.00 |
| ModivCare (MODV) | United States | $0.046B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.041B | 0.00 |
| Biodesix (BDSX) | United States | $0.040B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.035B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.012B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.009B | 0.00 |
| XWELL (XWEL) | United States | $0.005B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| SeaStar Medical Holding (ICU) | United States | $0.004B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.002B | 0.00 |
| INVO Fertility (IVF) | United States | $0.002B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |